# A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

> **NCT05960097** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 692 (actual)

## Conditions studied

- SARS-CoV-2
- COVID-19

## Interventions

- **BIOLOGICAL:** CV0701 mRNA COVID-19 Vaccine (Low dose)
- **BIOLOGICAL:** CV0701 mRNA COVID-19 Vaccine (Medium dose)
- **BIOLOGICAL:** CV0701 mRNA COVID-19 Vaccine (High dose)
- **BIOLOGICAL:** CV0601 mRNA COVID-19 Vaccine
- **BIOLOGICAL:** Control vaccine
- **BIOLOGICAL:** CV0801 mRNA COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT05960097
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 692 (ACTUAL)
- **Last updated:** 2025-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05960097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05960097, "A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05960097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*